Langenfeld, Germany, June 03, 2026 (GLOBE NEWSWIRE) -- Booking Health today announced the release of findings examining international patient access to personalized dendritic cell therapy for glioblastoma in Germany. The findings, based on a documented Canadian patient case and supporting clinical research, highlight how cross-border treatment pathways may provide patients with aggressive brain tumors access to individualized immunotherapy options that are not widely available within all healthcare systems.
New GeneSight ® Mental Health Monitor Reveals 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan
New GeneSight ® Mental Health Monitor Reveals 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan
NEWTON, Mass., June 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it...
The article breaks down pricing factors and helps readers understand what influences hearing aid expenses.SOUTHLAKE, Texas, June 3, 2026 /PRNewswire/ -- What should residents...
Zachary W. Mazin joins from McKool Smith, deepening the firm's capabilities at the intersection of complex financial fraud, restructuring and accounting malpractice litigationNEW YORK,...
Upgraded four-stage cooling system and 7-zone support target the most common cause of disrupted sleep in American homesWILMINGTON, Del., June 3, 2026 /PRNewswire/ --...
ProBio and GCP ClinPlus today announced a strategic collaboration designed to accelerate Investigator-Initiated Trials (IITs) in China and provide integrated, end-to-end clinical and development...
WARWICK, NY, June 03, 2026 (GLOBE NEWSWIRE) -- Ozop Energy Solutions, Inc. (OTC: OZSC, the “Company”) today highlighted a major cultural milestone at Unity Electro Fest, a large-scale Canadian electronic music festival in which Varon Wellness, a subsidiary of Varon Corp, holds a strategic ownership interest. Ozop and Varon Corp are currently completing customary pre-closing conditions in connection with the previously announced transaction with OZOP..
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2
Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.